For BRD2, low-to-moderate immunopositivity in adenocarcinomas was associated with a non-significant difference in survival (p = 0.11, https://www.proteinatlas.org/ENSG00000204256-BRD2/pathology/colorectal+cancer). This evidence concerns the gene BRD2 and cancer.